53. シェーグレン症候群 Sjogren syndrome Clinical trials / Disease details
臨床試験数 : 305 / 薬物数 : 325 - (DrugBank : 104) / 標的遺伝子数 : 58 - 標的パスウェイ数 : 188
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04563195 (ClinicalTrials.gov) | December 1, 2021 | 12/9/2020 | BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome | BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | Drug: tibulizumab (LY3090106) | Matthew C. Baker | NULL | Not yet recruiting | 18 Years | 85 Years | All | 12 | Phase 2/Phase 3 | United States |